These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Identification of Long Non-Coding RNA Profiles and Potential Therapeutic Agents for Fibrolamellar Carcinoma Based on RNA-Sequencing Data. Kim J; Kim Y; Lee B Genes (Basel); 2023 Aug; 14(9):. PubMed ID: 37761849 [TBL] [Abstract][Full Text] [Related]
6. Molecular profiling and analysis of genetic aberrations aimed at identifying potential therapeutic targets in fibrolamellar carcinoma of the liver. El Dika I; Bowman AS; Berger MF; Capanu M; Chou JF; Benayed R; Zehir A; Shia J; O'Reilly EM; Klimstra DS; Solit DB; Abou-Alfa GK Cancer; 2020 Sep; 126(18):4126-4135. PubMed ID: 32663328 [TBL] [Abstract][Full Text] [Related]
7. DNAJB1-PRKACA fusion protein-regulated LINC00473 promotes tumor growth and alters mitochondrial fitness in fibrolamellar carcinoma. Ma RK; Tsai PY; Farghli AR; Shumway A; Kanke M; Gordan JD; Gujral TS; Vakili K; Nukaya M; Noetzli L; Ronnekleiv-Kelly S; Broom W; Barrow J; Sethupathy P PLoS Genet; 2024 Mar; 20(3):e1011216. PubMed ID: 38512964 [TBL] [Abstract][Full Text] [Related]
8. CRISPR/Cas9 Engineering of Adult Mouse Liver Demonstrates That the Dnajb1-Prkaca Gene Fusion Is Sufficient to Induce Tumors Resembling Fibrolamellar Hepatocellular Carcinoma. Engelholm LH; Riaz A; Serra D; Dagnæs-Hansen F; Johansen JV; Santoni-Rugiu E; Hansen SH; Niola F; Frödin M Gastroenterology; 2017 Dec; 153(6):1662-1673.e10. PubMed ID: 28923495 [TBL] [Abstract][Full Text] [Related]
9. DNAJB1-PRKACA in HEK293T cells induces LINC00473 overexpression that depends on PKA signaling. Kim SS; Kycia I; Karski M; Ma RK; Bordt EA; Kwan J; Karki A; Winter E; Aktas RG; Wu Y; Emili A; Bauer DE; Sethupathy P; Vakili K PLoS One; 2022; 17(2):e0263829. PubMed ID: 35167623 [TBL] [Abstract][Full Text] [Related]
10. Increased Protein Kinase A Activity Induces Fibrolamellar Hepatocellular Carcinoma Features Independent of DNAJB1. Shirani M; Levin S; Shebl B; Requena D; Finkelstein TM; Johnson DS; Ng D; Lalazar G; Heissel S; Hojrup P; Molina H; de Jong YP; Rice CM; Singhi AD; Torbenson MS; Coffino P; Lyons B; Simon SM Cancer Res; 2024 Aug; 84(16):2626-2644. PubMed ID: 38888469 [TBL] [Abstract][Full Text] [Related]
11. Expression of the Long Intergenic Non-Protein Coding RNA 665 (LINC00665) Gene and the Cell Cycle in Hepatocellular Carcinoma Using The Cancer Genome Atlas, the Gene Expression Omnibus, and Quantitative Real-Time Polymerase Chain Reaction. Wen DY; Lin P; Pang YY; Chen G; He Y; Dang YW; Yang H Med Sci Monit; 2018 May; 24():2786-2808. PubMed ID: 29728556 [TBL] [Abstract][Full Text] [Related]
12. Multiomic analysis of microRNA-mediated regulation reveals a proliferative axis involving miR-10b in fibrolamellar carcinoma. Francisco AB; Kanke M; Massa AP; Dinh TA; Sritharan R; Vakili K; Bardeesy N; Sethupathy P JCI Insight; 2022 Jun; 7(11):. PubMed ID: 35482409 [TBL] [Abstract][Full Text] [Related]
13. Methylome sequencing for fibrolamellar hepatocellular carcinoma depicts distinctive features. Malouf GG; Tahara T; Paradis V; Fabre M; Guettier C; Yamazaki J; Long H; Lu Y; Raynal NJ; Jelinek J; Mouawad R; Khayat D; Brugières L; Raymond E; Issa JP Epigenetics; 2015; 10(9):872-81. PubMed ID: 26224146 [TBL] [Abstract][Full Text] [Related]
15. Single-Cell RNA Sequencing Identifies Yes-Associated Protein 1-Dependent Hepatic Mesothelial Progenitors in Fibrolamellar Carcinoma. Jewell ML; Gibson JR; Guy CD; Hyun J; Du K; Oh SH; Premont RT; Hsu DS; Ribar T; Gregory SG; Diehl AME Am J Pathol; 2020 Jan; 190(1):93-107. PubMed ID: 31669305 [TBL] [Abstract][Full Text] [Related]
16. GalNAc-conjugated siRNA targeting the DNAJB1-PRKACA fusion junction in fibrolamellar hepatocellular carcinoma. Neumayer C; Ng D; Requena D; Jiang CS; Qureshi A; Vaughan R; Prakash TP; Revenko A; Simon SM Mol Ther; 2024 Jan; 32(1):140-151. PubMed ID: 37980543 [TBL] [Abstract][Full Text] [Related]
17. Transcriptional profiling of pure fibrolamellar hepatocellular carcinoma reveals an endocrine signature. Malouf GG; Job S; Paradis V; Fabre M; Brugières L; Saintigny P; Vescovo L; Belghiti J; Branchereau S; Faivre S; de Reyniès A; Raymond E Hepatology; 2014 Jun; 59(6):2228-37. PubMed ID: 24443104 [TBL] [Abstract][Full Text] [Related]
18. Oncogenic Addiction of Fibrolamellar Hepatocellular Carcinoma to the Fusion Kinase DNAJB1-PRKACA. Neumayer C; Ng D; Jiang CS; Qureshi A; Lalazar G; Vaughan R; Simon SM Clin Cancer Res; 2023 Jan; 29(1):271-278. PubMed ID: 36302174 [TBL] [Abstract][Full Text] [Related]
19. Identification of a five-long non-coding RNA signature to improve the prognosis prediction for patients with hepatocellular carcinoma. Zhao QJ; Zhang J; Xu L; Liu FF World J Gastroenterol; 2018 Aug; 24(30):3426-3439. PubMed ID: 30122881 [TBL] [Abstract][Full Text] [Related]
20. Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma. Gu JX; Zhang X; Miao RC; Xiang XH; Fu YN; Zhang JY; Liu C; Qu K World J Gastroenterol; 2019 Jan; 25(2):220-232. PubMed ID: 30670911 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]